Mumbai: Cardiac device maker S3V Vascular Technologies Limited has announced plans to move its indigenously developed Balloon-Expandable Transcatheter Aortic Valve Replacement (TAVR) system into preclinical study.
Preclinical evaluation will validate its safety and design performance. Pending successful clinical trials and regulatory approvals, the company aims for a commercial launch within the next 12 to 18 months.
TAVR is a minimally invasive therapy for patients with severe aortic stenosis. While traditional treatment requires open-heart surgery, TAVR allows clinicians to replace the valve via a catheter, significantly reducing recovery time for elderly or high-risk patients.
According to the company, existing valve replacement systems which are imported in India cost between ₹13 lakh and ₹23 lakh, making them highly inaccessible for many Indian patients.
Today, India does around 4000 TAVR’s annually, the need is close to 50,000. Challenges include high device cost and limited reimbursement options. S3V aims to significantly reduce the treatment costs by providing a high-quality, locally developed alternative.
“This launch represents a vital step toward democratising advanced cardiac care, ” said Dr. Vijaya Gopal, Managing Director of S3V Vascular Technologies Limited. “Our vision is to make life-saving structural heart therapies accessible to the broader population by reducing device costs through domestic innovation.”
Source link
#S3V #Vascular #Tech #advance #India #valve #replacement #system #preclinical #stage
